Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01132547 · ClinicalTrials.gov registry record · Phase 3
Cyproheptadine in Preventing Weight Loss in Children Receiving Chemotherapy for Cancer
A Phase 3 study, sponsored by University of South Florida.
- Terminated
- Registry status
- Phase 3
- Development phase
- 22
- Enrollment target
NCT01132547 is a Phase 3 study that was terminated before completion, run by University of South Florida. The registered enrollment target is 22 participants.
The verdict
NCT01132547, a Phase 3 study, was terminated before completion, sponsored by University of South Florida.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 22 participants
- Enrollment target
Study Summary
RATIONALE: Cyproheptadine hydrochloride may prevent weight loss caused by cancer or cancer treatment. It is not yet known whether cyproheptadine is more effective than a placebo in preventing weight loss in young patients receiving chemotherapy for cancer. PURPOSE: This randomized phase III trial is studying cyproheptadine hydrochloride to see how well it works in preventing weight loss in young patients receiving chemotherapy for cancer.
Interventions
- OTHER placebo
- DRUG cyproheptadine hydrochloride
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2010-06 |
| Est. Completion | 2014-01 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01132547
The ClinicalTrials.gov registry entry for NCT01132547 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 22 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of South Florida, which has 252 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which placebo is the first listed.
NCT01132547 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01132547 about?
NCT01132547 is a clinical study titled "Cyproheptadine in Preventing Weight Loss in Children Receiving Chemotherapy for Cancer". RATIONALE: Cyproheptadine hydrochloride may prevent weight loss caused by cancer or cancer treatment. It is not yet known whether cyproheptadine is more effective than a placebo in preventing weight loss in young patients receiving chemotherapy for cancer. PURPOSE: This randomized phase III trial i...
What is the current status of trial NCT01132547?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 22 participants. The study started on 2010-06. Estimated completion is 2014-01.
What interventions are being tested in trial NCT01132547?
The interventions under investigation include: placebo (OTHER), cyproheptadine hydrochloride (DRUG).
Who is sponsoring clinical trial NCT01132547?
This trial is sponsored by University of South Florida, which has 252 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.